Centre Regional Lutte Contre Le Cancer

Clinical research in recurrent and metastatic head and neck squamous cell carcinoma focuses on treatment after immune checkpoint inhibitor failure, with attention to objective response rate and disease control in later-line settings.

• Recurrent/metastatic disease
• Post-immunotherapy treatment
• Combination systemic therapy

The therapeutic interest centers on integrating platinum-based chemotherapy, taxane therapy, and EGFR-targeted treatment in squamous cell carcinoma of the head and neck.